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Abstract
Background: Although androgens are depleted in castration resistant prostate cancer (CRPC), metastases still express
nuclear androgen receptor (AR) and androgen regulated genes. We recently reported that C-terminal truncated
constitutively active AR splice variants contribute to CRPC development. Since specific antibodies detecting all C-terminal
truncated AR variants are not available, our aim was to develop an approach to assess the prevalence and function of AR
variants in prostate cancer (PCa).
Methodology/Principal Findings: Using 2 antibodies against different regions of AR protein (N- or C-terminus), we
successfully showed the existence of AR variant in the LuCaP 86.2 xenograft. To evaluate the prevalence of AR variants in
human PCa tissue, we used this method on tissue microarrays including 50 primary PCa and 162 metastatic CRPC tissues.
RT-PCR was used to confirm AR variants. We observed a significant decrease in nuclear C-terminal AR staining in CRPC but
no difference between N- and C-terminal AR nuclear staining in primary PCa. The expression of the AR regulated proteins
PSA and PSMA were marginally affected by the decrease in C-terminal staining in CRPC samples. These data suggest that
there is an increase in the prevalence of AR variants in CRPC based on our ability to differentiate nuclear AR expression
using N- and C-terminal AR antibodies. These findings were validated using RT-PCR. Importantly, the loss of C-terminal
immunoreactivity and the identification of AR variants were different depending on the site of metastasis in the same
patient.
Conclusions: We successfully developed a novel immunohistochemical approach which was used to ascertain the
prevalence of AR variants in a large number of primary PCa and metastatic CRPC. Our results showed a snapshot of overall
high frequency of C-terminal truncated AR splice variants and site specific AR loss in CRPC, which could have utility in
stratifying patients for AR targeted therapeutics.
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Introduction
Metastatic prostate cancer (PCa) that recurs following castration
or androgen deprivation therapy (ADT), termed castration
resistant prostate cancer (CRPC), portends a poor outcome with
high lethality. Although circulating levels of androgens are
depleted in CRPC, tumor progression is often concomitant with
elevated levels of the androgen receptor (AR), activation of the
AR, and the expression of AR-regulated genes. However, an
increase in AR expression by itself is generally not sufficient to
engage the AR transcriptional program [1]. Various mechanisms
have been shown to lead to AR transactivation and engage the AR
program following castration. These include persistence of
intratumoral androgens, ectopic androgen synthesis by the tumor
either from adrenal androgens or intratumoral de novo synthesis,
and enhanced androgen transport into the tumor by solute carrier
organic anion transporter proteins [2–6]. Several cytokines and
growth factor pathways have been shown to be able to activate the
AR through direct binding or cross-talk mechanisms [7–13].
Alterations in AR co-regulators may also modulate AR activity
when androgen levels are decreased [14–18]. Functionally, each of
these mechanisms promoting AR activation in CRPC requires the
carboxy-terminus region of the mature protein which contains the
ligand-binding domain (LBD).
In addition to mechanisms leading to AR activation in CRPC
that require ligand, recent evidence points to the existence of
alternatively spliced forms of AR mRNAs that encode receptors
devoid of the LBD, but retaining the ability to engage
transcriptional machinery and promote the regulation of
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26]. Not only are these C-terminal truncated AR variants
constitutively active, but their structure predicts a general
resistance to therapeutics such as AR-antagonists that require
binding to the LBD for activity. To date, we and others have
identified three AR splice variants in human tissue specimens
[22,25–27]. AR-V1 encodes a splice variant comprised of exons
1–3 and ending in a cryptic exon (CE1), AR-V7 (also named AR3)
encodes a protein with exons 1–3 and a terminal cryptic exon
(CE3), and AR
v567es encodes a protein comprised of exons 1–4,
and because of a frame-shift due to loss of exons 5–7, exon 8 has a
stop codon generated after the first 10 amino acids resulting in a
shortened exon8. [22,25–27]. Additional AR splice variants have
been detected in human PCa cell lines [21,24,26–28].
Several studies evaluating the expression of AR splice forms in a
small number of prostate cancers suggest that AR variants are
more readily detected in CRPC compared to hormone-naı ¨ve
cancers, and may emerge due to the selective pressure of AR
targeted therapy [22,25,26]. A recent study used qRT-PCR to
identify AR variant transcripts in 40 bone metastasis, of which 30
were from CRPC, and found an association between the
expression of AR variants and survival [29]. Determining the
prevalence of AR variants in different clinical states of prostate
cancer has been challenged by requirements for well-preserved
frozen tissue samples for transcript-based analyses, and the lack of
antibodies capable of specifically detecting most AR variant
proteins. To overcome this limitation, we sought to take advantage
of the fact that new AR carboxy-termini encoded by alternatively
spliced forms of the AR mRNA cannot be recognized by
antibodies directed against the normal C-terminus of the full-
length AR (AR
FL). We hypothesized that this feature of AR
variants afforded an opportunity to identify AR protein variants in
formalin-fixed tissues by comparing the differential staining of
antibodies recognizing either N- or C-terminus of the AR.
Therefore, in the present study, we used antibodies against the
N- or C-terminus of the AR protein to interrogate a large number
of benign prostate tissue, primary hormone naı ¨ve PCa and a series
of metastatic CRPC to ascertain the prevalence of C-terminal
truncated AR variants.
Materials and Methods
Reagents
The antibodies used in this study and the working conditions are
listed in Table 1.
Tissue
Human primary and metastatic PCa tissues were obtained as
part of the PCa research program and University of Washington
Medical Center Prostate Cancer Donor Rapid Autopsy Program,
which is approved by the University of Washington Institutional
Review Board. The Institutional Review Board of the University
of Washington Medical Center approved all procedures involving
human subjects, and all subjects signed written informed consent.
Human tissue microarrays (TMAs) consists of 42 patients from
Prostate Cancer Donor Rapid Autopsy Program (including 65 soft
tissue metastases and 120 bone metastases) [30], 55 radical
prostatectomy patients (including 28 normal prostate, 24 hyper-
plastic prostate, and 50 primary prostate cancer tissues) were used.
The LuCaP 86.2 prostate cancer xenograft is an adenocarcinoma
that does not respond to castration and was derived from a human
PCa bladder metastasis. The LuCaP 35 prostate cancer xenograft
is an adenocarcinoma that responds to castration and was derived
from a PCa lymph node metastasis. These xenografts fail to grow
as cell lines, thus they are maintained by serial passage in SCID
mice. The LuCaP 86.2 xenograft expresses a known C-terminal
truncated AR variant AR
v567es that is constitutively active. The
LuCaP 35 xenograft only expresses wide type AR [25]. Fresh
LuCaP 35 and 86.2 xenograft tissues were used for western
analysis. Twenty two CRPC metastatic tissues from rapid autopsy
patients corresponding to the tissues on the human TMA had been
snap frozen in liquid nitrogen after resection and stored at -80uC
until use. Clinical data relating to the 42 autopsy patients is shown
in Table 2.
Reverse Transcription-PCR (RT-PCR) and quantitative RT-
PCR (qRT-PCR)
Total tissue RNA was isolated from minced fresh tissue using
Trizol reagent (Invitrogen) according to the manufacturer’s
instructions. Two micrograms of total RNA was digested with
DNase I, and reverse transcribed using Superscript First-Strand
Synthesis System (Invitrogen). PCR was performed using Ampli-
Taq GoldH PCR Master Mix (Applied Biosystems). PCR products
were run on 2% agarose gel and image pictures were taken by
using AlphaDigiDoc Pro imaging system from Alpha Innotech
(San Leandro, CA). qRT-PCR reactions were done using an
Applied Biosystems 7900 sequence detector with 5 ng of cDNA,
200 nM of each primer pair and Power SYBR Green PCR Master
Table 1. Antibodies used in this study.
Antibody Company Clone/lot
IHC
Dilution
WB
Dilution
Androgen Receptor Biogenex F39.4.1 1:60
Androgen Receptor Santa Cruz 441 1:4000
Androgen Receptor Santa Cruz C-19 1:200 1:2000
Chromogranin A Dako DAK-A3 1:100
Synaptophysin Santa Cruz D-4 1:200
PSA Dako A0562 1:200
PSMA Invitrogen 18-7318 1:35
Ki67 Dako MIB-1 1:100
AKT-1 Calbiochem Ab-1 1:2000
Mouse IgG Abcam MOPC-21
Rabbit IgG Vector
laboratories
S0818
doi:10.1371/journal.pone.0027970.t001
Table 2. Clinical data of 42 CRPC patients*.
Min-max
values Mean Average
Age at PCa Diagnosis 42–93 63 64
Diagnosis to Death (years) 0–20 5 6.5
Castration to Death (month) 1–92 19.5 30
PSA at Diagnosis (ng/ml) 1.7–4000 12.4 267.22
Final PSA (ng/ml) 0.15–7402 413.2 843.48
*All 42 patients had castrate resistant prostate cancer at the time of autopsy,
defined by the presence of a rising serum PSA following medical or surgical
castration. All patients’ tissues were obtained at autopsy under University of
Washington Medical Center Prostate Cancer Donor Rapid Autopsy Program.
doi:10.1371/journal.pone.0027970.t002
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Biosystems.
Gene expression levels were measured by relative quantification
between RNA samples, and fold expression changes were
determined by the 2–DDCT method [31]. All qRT-PCR
experiments were performed in triplicate, and the housekeeping
gene RPL13A was used as an endogenous control.
The primer sequences are listed in Table 3.
Cell Culture and stimulation
VCAP cells that expressed both AR
FL and AR
v567es variant
were grown to 80% confluence in 30 mm plates in RPMI 1640
medium with 5% serum, and then switched to RPMI-1640
medium with 5% charcoal stripped serum for 24 h. Dihydrotes-
tosterone (DHT) 10
29 M, MDV-3100 50 nM, or MDV-3100 plus
DHT were added to the cultures. After 24 h, total RNA was
collected from duplicate wells for qRT-PCR to detecting AR
FL,
AR
v567es and AR-V7 transcripts. The experiment was repeated 6
times with triplicates each time, and the qRT-PCR results were
normalized to DHT treatment group.
Western Blotting
Fresh tissue was homogenized and lysed with cold lysis buffer
(50 mM HEPES, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA,
1% Triton X-100) containing Halt
TM Phosphatase Inhibitor
Cocktail and protease inhibitors (Thermoscientific). Complete
lysates were separated on SDS-PAGE, transferred onto a
nitrocellulose membrane, blocked in 5% milk-PBS-Tween and
probed with respective overnight at 4uC. Membranes were
incubated with a horseradish peroxidase-conjugated secondary
antibody (Cell Signaling), and developed with ECL (Pharmacia
Biotech). The membranes were stripped for 30 min in Stripping
Buffer (Thermoscientific) and re-probed with anti-b-actin antibody
as a loading control (Sigma-Aldrich). Independent experiments
validated that this stripping procedure did not lead to loss of signal.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue sections (5mm) were
deparaffinized and rehydrated. Antigen retrieval was performed
with 10 mM citrate buffer (pH 6.0) in a pressure cooker (20 psi for
10 min). Endogenous peroxide and biotin/avidin was blocked for
15 min with respective agents (Vector Laboratories). After
incubating with 5% normal goat-horse-chicken serum at room
temperature for 1 h, sections were incubated with primary
antibodies (table 1) at 4uC overnight followed by biotinylated
secondary antibodies and sABC reagent (Vector Laboratories).
DAB (Invitrogen) was used as the chromogen, and hematoxylin as
counterstain. Mouse or Rabbit IgG, as appropriate, at the same
concentration as the primary antibody was used as a negative
control and did not show nonspecific staining [32].
Immunohistochemical assessment
A few unusable cores were found in the TMAs due to tissue core
missing, cancer necrosis, or insufficient cancer cells. These cores
were excluded from the results.
Immunostaining was assessed using a quasi-continuous nuclear
AR score, created by multiplying each intensity level (0 for no
stain, 1 for weak stain, and 2 for intense stain) by the
corresponding percentage of positive cells, and then summing
the results.
Ki-67 staining was measured by randomly choosing up to 4
fields of 250 mm
2 in each tissue site. Total cell number and Ki67
positive cell number were counted, and the final Ki-67 index was
calculated using positive cell number divided by total cell number.
AR antibodies used in this study targeted three distinct regions
of the human AR protein. The immunogens of AR F39.4.1
(against aa301–320) and AR441 (against aa299–315) were located
in the N-terminal of AR while AR C-19 (against aa900–919) in the
C-terminal. Therefore, we describe AR F39.4.1 and AR441 as N-
terminal AR antibodies and AR C-19 as a C-terminal AR
antibody. Specific patterns of AR nuclear immunostaining were
assessed as: N+C+ (similar positive N-terminal and C-terminal AR
staining in nucleus); N+CQ (C-terminal AR score dropped more
than 50% compared to N-terminal in nucleus) and N-C- (similar
negative N- and C-terminal AR staining in nucleus). The tissues in
NQC+ group were not included because they were rare, and not
relative to C-terminal truncated AR variants.
Statistical analysis
Statistical analyses of the results were performed using Prism
software (Prism Graphpad), where we used the Mann-Whitney
test, and p values #0.05 were chosen as statistical significant.
Results
Alternatively spliced forms of AR could be identified
using N- and C-terminal antibodies
Several AR transcript variants have been described that encode
AR polypeptides devoid of the C-terminal LBD due to alternative
Table 3. Primer sequences.
Target gene Primer Sequence (59 to 39)
AR
FL F: ACATCAAGGAACTCGATCGT ATCATTGC
R: TTGGGCACTTGCACAGAGAT
AR
v567es F: TGCTGGACACGACA ACAA
R: GCAGCTCTCTCGCAATCA
AR-V7 F: CCATCTTGTCG
TCTTCGGAAATGTTATGAAGC
R: TTTGAATGAGGCAAGTCAGCCTTT CT
AR3 F: CTACTCCGGACCTTACGGGGACATGC G
R: TGCCAACCCGGAATTTTTCTCCC
RPL13A F:CCTGGAGGAGAAGAGGAAAGAGA
R:TTGAGGACCTCTGTGTATTTGTCAA
CDK1 F: GGAAACCAGGAAGCCTAGCATC
R: GGATGATTCAGTGCCATTTTGCC
CYCLINA2 F: CTCTACACAGTCACGGGACAAAG
R: CTGTGGTGCTTTGAGGTAGGTC
C-MYC F: CCTGGTGCTCCATGAGGAGAC
R: CAGACTCTGACCTTTTGCCAGG
UGT2B17 F: ACCAGCCAAACCCTTGCCTAAG
R:GGCTGATGCAATCATGTTGGCAC
CDC20 F: CGGAAGACCTGCCGTTACATTC
R: CAGAGCTTGCACTCCACAGGTA
AKT1 F: TGGACTACCTGCACTCGGAGAA
R: GTGCCGCAAAAGGTCTTCATGG
UBE2C F: TGGTCTGCCCTGTATGATGT
R: AAAAGCTGTGGGGTTTTTCC
doi:10.1371/journal.pone.0027970.t003
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available to detect all of these variants in tissue. As antibodies have
been developed toward specific N-terminal and C-terminal
domains of AR protein, we sought to determine if these reagents
could be used to distinguish PCa expressing different AR forms.
To validate this approach, we first evaluated two PCa xenograft
lines derived in the laboratory of one of the authors (RLV) and
known to express different AR-encoding mRNAs. The LuCaP
86.2 xenograft, derived from a human PCa bladder metastasis and
maintained by serial passage in uncastrated SCID mice, has been
shown to possess a C-terminal truncated AR splice variant that
skipped exons 5–7 and encodes an alternate reading frame from
exon 8, designated AR
v567es. The LuCaP 35 xenograft was derived
from a PCa lymph node metastasis and expresses full-length AR
(AR
FL)-encoding mRNA comprised of 8 exons and a protein of
appropriate size for this transcript [25].
We analyzed proteins derived from LuCaP 86.2 and LuCaP 35
xenografts by Western blot using antibodies recognizing N-
terminus (AR 441) or C-terminus (AR C-19) of AR
FL protein. In
the LuCaP 35 tumor, both AR antibodies detected a similar
110 KDa AR polypeptide that corresponded to the size of AR
FL.
In the LuCaP 86.2 tumor, beside a weak 110 KDa band, N-
terminal AR antibody also identified an 80 KDa AR isoform that
corresponded to the predicted size of the C-terminal truncated AR
splice variant-AR
v567es while C-terminal AR antibody did not
(Figure 1A).
Similar to the Western blot result, immunohistochemical
analysis (IHC) of LuCaP 86.2 showed very weak nuclear staining
using the C-terminal AR (AR c-19) antibody, but intense nuclear
staining in the serial section with AR antibody against N-terminal
(AR F39.4.1). The LuCaP 35 tumor, shown to express only AR
FL
by Western analysis, did not show any difference between N- and
C-terminal AR staining by IHC (Figure 1B). These data confirmed
that comparing the N-terminal AR with C-terminal AR expression
could identify C-terminal truncated AR variants/mutations in
PCa tissue.
AR
v567es has been shown to be constitutively active [25], this is
consistent with the fact that different AR immunoreactivity with
N- and C-terminal antibodies was observed in the nucleus. To
further confirm nuclear AR activity, we stained for the AR-
regulated PSA and PSMA proteins. LuCaP 86.2 was immunore-
active for both PSA and PSMA. To confirm that LuCaP 86.2 was
not a neuroendocrine xenograft line, we stained with neuroendo-
crine biomarkers Chromogranin A (CHG-A) and Synaptophysin
(SYN). LuCaP 86.2 showed negative CHG-A immunoreactivity,
and weak to moderate SYN immunoreactivity as a fine, granular
reaction product that was predominantly localized in the
peripheral cytoplasm of cells. Furthermore, approximately 20%
of the tumor cells were Ki67 positive indicating LuCaP 86.2 had a
moderate proliferation rate (Figure 1C). Corresponding IHC
results for LuCaP 35 are also shown in Figure 1D.
Variations in N-terminal and C-terminal AR expression
occurred rarely in benign epithelium and primary
untreated PCa
To determine the frequency of C-terminal truncated AR
variants in benign epithelium and untreated localized PCa, we
scored IHC staining of radical prostatectomy specimens. All 28
normal prostate specimens had concordant N-terminal and C-
terminal nuclear AR expression (N+C+) (Figure 2A a and b).
Among the 24 hyperplastic prostate samples, 21 cases (87.5%)
showed consistent N+C+ expression (Figure 2A c and d), only 1
(4.2%) had decreased C-terminal AR staining (N+CQ) and 2
(8.3%) did not have any AR immunoreactivity (N-C-). In 50
primary PCa samples, 46 cases (92%) expressed N+C+ AR
(Figure 2A e–h), 2 cases (4%) had decreased nuclear C-terminal vs.
N-terminal AR staining (N+CQ), while 2 cases (4%) were AR
negative (N-C-). Overall, there was no significant difference in the
ratio of N- vs. C-terminal nuclear staining intensity between
normal prostate and hyperplastic prostate samples (p=0.5756),
normal prostate and PCa samples (p=0.7428), and hyperplastic
prostate and PCa samples (p=0.7508) (Figure 2B).
Variations in N-terminal and C-terminal AR expression
occurred frequently in CRPC
To determine the frequency of variant AR expression in
metastatic PCa, we scored IHC staining of metastatic sites from 42
patients who died of advanced CRPC.
Among 162 metastatic sites, 103 (63.6%) sites showed consistent
nuclear AR expression with both antibodies (N+C+). However, 39
(24.1%) sites had a nuclear C-terminal AR score (N+CQ) that was
at least 50% less than the corresponding N-terminal AR score, and
Figure 1. Characterization of the LuCaP 86.2 subcutaneous
xenograft tumor. (A) Western blot analysis of AR expression in LuCaP
86.2 and LuCaP 35 xenograft tumors. (B) IHC staining for the N- and C-
terminal AR on LuCaP 86.2 (a and b) and LuCaP 35 (c and d) xenograft
tumors. (C) IHC staining for PSA (e), PSMA (f), Chromogranin-A (g),
Synaptophysin (h), Ki67 (i) and negative control (j) on LuCaP 86.2
xenograft. (D) IHC staining for PSA (k), PSMA (l), Chromogranin-A (m),
Synaptophysin (n), Ki67 (o) and negative control (p) on LuCaP 35
xenograft. (original magnification x200, insert x400).
doi:10.1371/journal.pone.0027970.g001
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(Figure 2C). These IHC results were in agreement with the
frequency of AR splice variants in metastatic PCa determined
using PCR methods to detect AR-V7/AR3 and AR
v567es
transcripts [25]. There was no difference in N-terminal AR
staining between primary and metastatic PCa (p=0.38, data not
show), but the frequency of decreased nuclear C-terminal AR
expression in metastatic CRPC was significantly higher than in
primary PCa (p=0.0027). The comparison of nuclear AR
expression between primary PCa and metastatic CRPC is shown
in Figure 2C.
AR-regulated gene expression was altered in metastatic
CRPC with diminished nuclear C-terminal AR
To determine if the decrease in nuclear C-terminal AR
expression was associated with an alteration in the expression of
AR regulated proteins, representing a loss of AR activity, we
examined AR regulated proteins PSA, PSMA, and TMPRSS2
expression in the metastatic CRPC samples (Figure 3A). While
barely missing significance, the expression of PSA in N+CQ
metastatic sites was lower than N+C+ metastatic sites (p=0.0505).
PSA expression in N-C- metastatic sites was significantly lower than
both N+C+ and N+CQ metastatic sites (p,0.001) (Figure 3B).
Additionally, the expression of PSMA in N+C+ metastatic sites was
higher than in N+CQ metastatic sites (p=0.0097), but PSMA in
N-C- metastatic sites was significantly lower than both N+C+
and N+CQ metastatic sites (p,0.0001) (Figure 3B). Finally, the
expression of TMPRSS2 in N+C+ metastatic sites was significantly
higher than N+CQ metastatic sites (p=0.045). TMPRSS2 in N-C-
metastatic sites was significantly lower than both N+C+ and N+CQ
metastatic sites (p,0.01) (Figure 3B). The loss of TMPRSS2
expression in N+CQ and N-C- metastatic sites was not as
pronounced as the loss of PSA and PSMA expression, suggesting
that TMPRSS2 maynot be regulated by the AR at thesamelevel as
PSA and PSMA in CRPC.
We next examined the genes that have been identified as having
their expression increased in response to AR C-terminus truncated
variants [26,29], including AKT1, CDC20, CDK1, C-MYC,
CyclinA2, UGT2B17 and UBE2C. Quantitative RT-PCR results
showed that AKT1, CDC20, CDK1 and UGT2B17 expression
were significantly higher in the N+CQ (n=11) compared to
N+C+ samples (n=7), (p, 0.05) (Figure 4A). UBE2C also trended
higher but did not reach significance (p,0.10). We further
detected AKT-1 protein expression by IHC. However, the
relatively low cycle number indicated relatively high levels of
gene expression in all cases. Therefore, when we also stained the
TMA for AKT1, relatively strong signal was present in most of the
tumor specimens on the TMA and given the semi quantitative
measurements, no differences were detected between the groups
by IHC (Figure 3B). Thus, cancers with N+CQ AR expressed
higher AKT1 levels, but this difference could not be detected on
IHC due to abundant protein in all groups.
The loss of nuclear C-terminal AR immunoreactivity was
associated with the expression of AR variants in
metastatic CRPC
We determined that loss of C-terminal AR immunoreactivity
occurred frequently in metastatic CRPC. This loss of C-terminal
immunoreactivity might be due to the expression of a number of
known (e.g. AR-V7/AR3, or AR
v567es) and unknown AR splice
variants. To determine if the N- and C-terminal immunoreactivity
was associated with AR transcript variants, we performed RT-
PCR on a subset of metastatic CRPC tissues and compared the
RT-PCR results to IHC results (Table 4). Of 4 N+C+ metastatic
samples examined by RT-PCR, all expressed AR
FL (one also had
limited expression of AR-V7). Of 8 metastatic samples classified as
N+CQ by IHC analysis, all expressed the AR
FL and 6 (75%) also
expressed at least one known AR variant (AR-V7/AR3 and
/or AR
v567es) by RT-PCR. These N+CQ metastatic samples also
exhibited lesser levels of PSA and PSMA immunoreactivity. None of
Figure 2. AR staining profiles of normal prostate, primary PCa and CRPC. (A) IHC staining for N- and C-terminal AR in normal prostate (NP)
(a and b), hyperplastic prostate (HP) (c and d) and primary PCa (e-h) (magnification x200). (B) Comparison of AR staining profiles among normal
prostate, hyperplastic prostate and primary PCa. (C) Comparison of AR staining profiles between primary PCa and metastatic CRPC.
doi:10.1371/journal.pone.0027970.g002
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FL examined by
RT-PCR, although one showed very low level of AR
v567esexpression.
These data demonstrated that IHC analysis using different AR
antibodies recognizing distinct AR protein regions was highly
concordant with transcripts encoding AR
FL and AR splice variants
that lack C-terminal exons.
AR variant mRNA was sensitive to androgen
concentration in vitro
VCAP cells were cultured in charcoal striped serum (CSS), and
then treated with Dihydrotestosterone (DHT), MDV-3100 or
MDV-3100 with DHT, separately. qRT-PCR showed that AR
FL
mRNA was suppressed by adding DHT, MDV-3100 and
DHT+MDV (Figure 5A). The variant AR
v567es mRNA was also
suppressed by DHT; however, it could be increased by addition of
androgen receptor antagonist MDV-3100 alone, and suppressed
to the level of CSS when DHT was added with MDV-3100
(Figure 5B). AR-V7 mRNA responded in a similar manner as
AR
FL (Figure 5C).
Heterogeneous expression of AR was observed in
individual patients
We identified C-terminal truncated AR proteins in multiple
metastatic sites from each of 42 CRPC patients (Figure 6). Of the
42 patients, 16 (38%) had no loss of C-terminal AR expression, 23
(55%) had at least one metastatic site with decreased nuclear C-
Figure 3. Expression of AR variants and AR regulated proteins in metastatic CRPC. (A) IHC staining for N-terminal AR (a), C-terminal AR (b),
PSA (c), PSMA (d), TMPRSS2 (e), AKT-1 (f), Ki-67(g), Negative control (h) on a metastatic CRPC tissue (magnification x200, insert x400). (B) PSA, PSMA,
TMPRSS2 and AKT-1 staining profiles of CRPC.
doi:10.1371/journal.pone.0027970.g003
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with no AR expression. These data highlight the heterogeneity of
AR expression among different metastatic sites within the same
patient.
Additionally, to determine if AR status promoted the rate of
tumor growth, we divided the CRPC bone metastasis samples into
three groups: N+C+ (n=93), N+CQ (n=39), and N-C- (n=18).
The Ki67 index for the N+C+ sites was 18%. This was not
significantly different from the N+CQ sites (20.8%) (p=0.4225) or
the N-C- sites (17.8%) (p=0.95).
Discussion
Traditional concepts of AR translocation to the nucleus that
involve ligand binding, dissociation from chaperones and nuclear
translocation imply that without androgen ligand, AR would be
found primarily in the cytoplasm and CRPC tumor progression
would be driven by mechanisms other than those involving AR.
However, this is not the case excepting most neuroendocrine
tumors. CRPC usually possess a transcriptionally active AR that
modulates the expression of AR regulated messenger RNAs
[1,33]. Furthermore, in most studies on CRPC tissues, the AR has
been found in the nucleus.
Multiple mechanisms have been proposed to explain AR
nuclear localization and some or all may be responsible for that
seen in CRPC [34,35]. Most of the proposed mechanisms would
be able to translocate the AR to the nucleus since they require
ligand binding to the LBD. If this was the case, assuming that
there are no differences in AR structures, we would expect to see
no differences in AR immunostaining with N- or C-terminal
directed antibodies in metastatic CRPC. However, as we show in
this study, there is a significant difference between nuclear N- and
C- terminal AR antibodies in the metastatic tissues. This suggests
that the mechanism(s) other than the ones mentioned above could
also be involved during AR translocation into the nucleus without
ligand in CRPC.
Figure 4. Quantitative RT-PCR of genes associated with AR C-terminal truncated variants. (A) Profile of seven AR variant associated genes
expression in human metastatic tissues. (B) The same genes were measured in LuCaP 86.2 and LuCaP 35 xenografts. The housekeeping
gene RPL13A was used as an endogenous control.
doi:10.1371/journal.pone.0027970.g004
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PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27970Although antibodies have been developed for the AR-V7/AR3
and AR
v567es splice variants, at least 20 AR splice variants have
been reported to date. With specific antibodies available for only 2
of the variants, the use of specific antibody staining on tissue to
detect castration-induced C-terminal truncated AR variants is not
feasible [20–25]. Here, we develop a novel and rapid immuno-
histochemical approach that compares N- and C-terminal AR
immunoreactivity, which can successfully show the overall
frequency of C-terminal truncated AR splice variants in patients.
The data reported here correlating the expression of AR protein
by IHC with 2 antibodies and validation of the expression of AR
splice variants by RT-PCR, strongly suggest that the variation
between AR N- and C-terminus immunoreactivity results from the
expression of alternative AR mRNAs. However, alternative
explanations should be entertained. The primary tumors and soft
tissue metastases were formalin fixed and paraffin embedded while
the metastatic lesions of bone were formalin fixed and decalcified
with 10% formic acid before embedding in paraffin. We observed
no significant difference in AR staining in soft tissue versus bone
metastasis (p.0.05, data not shown). Furthermore, we have not
seen differences with other antibodies between bone and soft tissue
preparation methods using the same tissues and methods [36,37].
Therefore we have not been able to identify a technical reason for
the differences in staining. Thus, we conclude that the observed
differential staining is due to the presence of variant AR transcripts
that lack part or all of the C-terminus.
As we have recently reported, these variants are associated with
androgen deprivation therapy (ADT) and occur relatively rapidly
if ADT results in a significant decrease in circulating and
intratumoral androgens [25]. Both AR variant mRNA and
protein are very sensitive to androgen concentration in vitro.W e
have also shown here that IHC on the LuCaP 86.2 xenograft that
predominantly expresses one of the AR C-terminal truncated
splice variants had a similar staining pattern to 24% of the
metastatic CRPC tissues (Figure 1 and Figure 3). Since the
constitutively active AR variants could translocate to the nucleus
without ligand, they would account for the different staining results
in the nucleus using 2 AR antibodies. However, it should also be
noted that the decreased immunoreactivity in the nucleus with C-
terminal AR antibody is not an all or none phenomenon, and
that a percentage of C-terminal AR staining is also found in the
nucleus of these tissues. This would not be unexpected since we
have shown that AR
v567es dimerizes with AR
FL and can cause
translocation of the AR
FL into the nucleus in the absence of ligand
[25].
One of our limitations was the inability of the assay to separate
constitutively active from inactive C-terminal deleted AR proteins.
To address this, we examined the expression of known AR
regulated proteins. We observed a decrease in PSA and PSMA
expression in the CRPC sites with the loss of C-terminal AR
staining. However the decrease in PSA and PSMA expression was
limited, suggesting constitutively active AR variants constitute a
significant portion of the C-terminal truncated AR variants in
CRPC.
In order to further explore the activity of AR variants among
the tissues, we selected a group of genes that are purported to be
AR variant regulated in human tissue [26,29]. The expression
levels of these genes were determined by quantitative RT-PCR in
subsets of tissues where cDNA was available. The variant-
associated genes that were elevated in the N+CQ tissues
compared to N+C+ were cell cycle genes associated with transition
through G2-M of the cell cycle or glucuronidation of androgens,
UGT2B17. Of interest, UGT2B17 is two logs higher in the LuCaP
86.2 line compared to LuCaP35. We have previously shown that
Table 4. Comparison of IHC with RT-PCR results in PCa Metastases.
GAPDH
AR-V7/
AR3 AR
v567es AR
FL
RT-PCR Independent Metastatic Sites Case Number AR PSA PSMA
IHC
+ 22 + Lymph Node 04-050G N+C++ +
+ 22 + Lymph Node 04-050R N+C++ +
+ 22 + Lymph Node 04-112H N+C+ 2 6
+ 6 2 + Lymph Node 05-217F N+C++ +
+ 22 2 Liver 03-192A N-C- 22
+ 22 2 Lymph Node 03-192D N-C- 22
+ 2 6 2 Liver 05-144E N-C- 22
+ 22 2 Lymph Node 05-144H N-C- 22
++ 2 + Liver 99-091C N+CQ 6 +
++ 2 + Lymph Node 00-140J N+CQ 6 +
+ 22 + Lymph Node 00-140N N+CQ 66
++ + + Liver 05-187E N+CQ ++
++ 2 + Liver 05-187F N+CQ ++
+ 6 2 + Liver 05-011F N+CQ 6 2
+ 22 + Lymph Node 05-214 I N+CQ + 2
++ 2 + Lymph Node 06-047H N+CQ ++
+Intense expression, 6Limited/weak expression, 2 No expression.
doi:10.1371/journal.pone.0027970.t004
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PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27970LuCaP 86.2 has very low levels of intratumoral steroid and high
AR
v567es regardless of whether the host is castrated or not [25]. In
contrast LuCaP 35 does not express AR splice variants unless
castrated and even then requires an inhibitor of androgen synthesis
e.g. abiraterone to express AR
v467es [25,38]. These data suggest that
not only do constitutively active AR splice variants increase AR-
regulated cell cycle genes, but by increasing UGT2B17 and
decreasing intracellular steroid, they further propagate an intracel-
lular milieu that favors further AR-variant synthesis.
We observed considerable heterogeneity in AR staining within
and between patients with CRPC. This suggests that the
truncation and/or loss of the AR are not necessarily early clonal
events in the development of PCa, rather late stage events
occurring independently of one another in CRPC. As proposed by
us and others, C-terminal AR loss, may be associated with
mutations, chromosomal rearrangements, or splicing events that
occur after androgen withdrawal [23,25]. Our results suggest that
a large proportion of the variants with a C-terminal loss are
constitutively active. Therefore, the mechanisms involved in the
acquisition of AR variant phenotype and the number of variants
that are constitutively active in CRPC will require further
investigation.
An important question for a patient in whom there is a
conversion to decreased C-terminal AR is whether or not it should
effect treatment decisions, especially since two new treatments for
PCa that has recurred following ‘‘traditional’’ ADT, i.e.
abiraterone and MDV-3100, require the LBD of the AR to be
effective [26,28]. We have shown that constitutively active AR
splice variants form heterodimers with the AR
FL and enhance
AR
FL transactivation by ligand [25]. Furthermore, Watson and
colleagues have subsequently shown that AR variants may require
AR
FL for activity and thus respond to MDV-3100 [28]. Here, we
show that AR
v567es is increased after androgen withdrawal and
androgen receptor inhibitor MVD-3100 treatment, which corre-
lates with our findings herein of an increase in AR variants with a
decrease in C-terminal IHC reactivity in CRPC. However, as
shown herein, there is heterogeneity among the metastatic sites
with regard to variant status and this confounds potential clinical
management decisions. Further studies are required to determine
whether assessments of AR splice variants will be useful in
stratifying patients for AR pathway-targeted therapies.
Hornberg et al published an independent study showing
increased mRNA levels of 3 specific AR splice variants (AR-V1,
AR-V7 and AR
v567es) in CRPC [29], which is consistent with
our findings. However, there are several important differences
between these two studies. First, our approach is able to detect the
distribution of all C-terminal truncated AR variant proteins in the
paraffin embedded tissue. Although AR-V1, AR-V7 and AR
v567es
are the three variants identified in human tissue so far, emerging
studies have suggested the existence of other AR variants which
should also be considered in regard to evaluation of total AR
functions. Our study showed a relatively complete profile of C-
terminal truncated AR variants in CRPC patients, and found AR
regulated gene products are associated with the distribution of AR
variants. Secondly, we investigated multiple metastatic sites for
each CRPC patient, whereas only single metastatic site per patient
was assessed in Hornberg’s study. Third, in our study, we did not
find any correlation between AR variants and time from diagnosis
to death or starting androgen ablation treatment to death. This
would not be unexpected since in Hornberg’s study, the AR
variants were detected at a specific event prior to death, i.e.
pathologic fracture; whereas our tissues were collected at the time
of death and thus the time from appearance of variants to death is
unknown. Furthermore, we have recently shown that recurrence
of human PCa xenografts following castration and inhibition of
steroid synthesis with the CYP17 inhibitor abiraterone may be
associated with either AR splice variants expression or intracrine
steroidogenesis [38]. As we pointed out earlier, the expression of
AR variants between metastatic sites is heterogeneous and is a very
common event seen within and between CRPC patients. This
should be taken into consideration when determining if an AR
variant(s) detected in a single metastatic site should affect clinical
treatment decisions.
Figure 5. AR variant mRNA was sensitive to androgen
concentration in vitro. (A)A R
FL mRNA was suppressed by DHT,
MDV-3100 and MDV-3100+DHT but not to the level seen by DHT alone.
(B)A R
v567es mRNA was suppressed in the presence of DHT, further
increased by addition of MDV-3100 and suppressed to the level of CSS
when DHT was added along with MDV-3100. (C) AR-V7 mRNA
responded in a similar manner as AR
FL.
doi:10.1371/journal.pone.0027970.g005
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